Home / Health / FDA Approves First Drug for Rare Genetic Disorder
FDA Approves First Drug for Rare Genetic Disorder
25 Mar
Summary
- The U.S. FDA has approved Denali Therapeutics' treatment for Hunter syndrome.
- This marks the company's first U.S. regulatory approval for the drug.
- The treatment, named Avlayah, is an enzyme replacement therapy.
On March 25, 2026, the U.S. Food and Drug Administration announced its approval of Denali Therapeutics' novel treatment for Hunter syndrome. This approval signifies a major milestone for Denali Therapeutics, representing its inaugural regulatory clearance within the United States. The newly approved therapy, to be marketed under the name Avlayah, is an enzyme replacement therapy specifically developed to address Hunter syndrome.
Hunter syndrome is a rare genetic disorder characterized by the accumulation of specific sugar molecules within the brain and body. This condition arises from a deficiency in the iduronate-2-sulfatase enzyme, which impairs the body's natural ability to break down large sugar molecules known as glycosaminoglycans. The successful FDA approval offers a new therapeutic option for patients affected by this debilitating condition.
